The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

“We are delighted to welcome the talented people of Biano,” said Viviane Monges, EuroAPI’s CEO. “Biano has demonstrated a strong commitment to supporting clients with innovative oligonucleotide developments. I look forward to all that we will achieve together to sustainably meet clients’ and patients’ needs around the world through our complementarities.”

As planned, Biano will retain its corporate brand and become a EuroAPI company.